Clinical trials
Steatohepatitis clinical trials
Below are recruiting steatohepatitis clinical trials, each written for real people, not researchers. We’re tracking 93 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07553663RecruitingPhase 1
Testing a new liver disease treatment for fatty liver
This study tests how your body processes a new medication called miricorilant, designed to help people with fatty liver disease (MASH). You'll have liver scans or recent biopsy results and metabolic conditions like diabetes or high blood pressure.
San Antonio, TexasAges 18–75 - NCT06569524RecruitingPhase 2
A new drug for NASH with liver scarring
This study tests a new injected drug (TQA2225/AP025) that may help reduce liver fat and inflammation in people with NASH (a type of fatty liver disease with scarring). It’s for adults who have had a recent liver biopsy and MRI confirming NASH and moderate liver fat.
Lu'an, AnhuiAges 18–75 - NCT07732400RecruitingPhase 1/Phase 2
Gene therapy for MASH (fatty liver disease)
This trial tests an experimental gene therapy (VV-14303) given as a single injection into the muscle to treat MASH, a common type of fatty liver disease with inflammation. The study will check if the treatment is safe and helps improve liver health.
Chandler, ArizonaAges 18–75 - NCT07704892RecruitingPhase 3
Study of efimosfermin for adults with cirrhosis from MASH
This trial tests a new drug, efimosfermin, to see if it is safe and effective for people with cirrhosis caused by MASH (a type of fatty liver disease). It may help improve liver health compared to a placebo.
Little Rock, ArkansasAges 18–75 - NCT07701993RecruitingPhase 3
Testing efimosfermin for MASH with compensated cirrhosis
This trial tests whether efimosfermin, an experimental drug, can safely help people with MASH (a fatty liver disease) that has led to cirrhosis (liver scarring) but the liver is still working well (compensated). Participants will be randomly assigned to receive the drug or a placebo.
Little Rock, ArkansasAges 18–75 - NCT07660848RecruitingPhase 2
A study of two new injections for fatty liver disease with MASH
This trial tests two new injections (HRS-4729 and HRS-9531) for people with MASH, a type of fatty liver disease. The study aims to see if these drugs can help reduce liver fat and improve liver health.
Beijing, Beijing MunicipalityAges 18–75 - NCT07581951RecruitingPhase 3
Study of HSK31679 for people with MASH (liver scarring)
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07491458RecruitingPhase 2
Study of HU6 versus placebo for adults with MASH
This trial tests if HU6 is safe and effective for people with MASH, a type of fatty liver disease. You will either receive HU6 or a placebo to see how it affects your liver health.
Chandler, ArizonaAges 30 years+ - NCT07476703Recruiting
Extended study on the SCAPIS Stockholm reexamined group
This trial studies data and samples from people already taking part in the main SCAPIS reexamination study in Stockholm. It looks for new findings to help understand heart and lung health.
StockholmAges 56–74 - NCT07303803RecruitingPhase 2
Testing Chiglitazar for fatty liver with diabetes
This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.
Beijing, Beijing MunicipalityAges 18–75 - NCT07288138RecruitingPhase 2
Study of a New Drug for MASH (Fatty Liver Disease)
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
Chandler, ArizonaAges 18–75 - NCT07265297RecruitingPhase 3
Hydroxychloroquine for fatty liver disease with inflammation
This trial tests if hydroxychloroquine, a medicine used for other conditions, can reduce liver inflammation in people with fatty liver disease. It aims to help those whose fatty liver has caused ongoing liver damage.
Taipei, TaiwanAges 18 years+ - NCT07188220Recruiting
Understanding patient views on fatty liver disease study
This study asks people with metabolic fatty liver disease and liver scarring about their experiences. It aims to learn what matters to you so doctors can improve care.
BarcelonaAges 18–75 - NCT07145151RecruitingPhase 2
Studying UBT251 for MASH liver disease
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
Beijing, Beijing MunicipalityAges 18–75 - NCT07013916Recruiting
Fructose and liver health in fatty liver disease
This study looks at how a sugar called fructose affects inflammation and metabolism in people with a type of fatty liver disease called MASH. It aims to find out if fructose plays a role in making the disease worse.
LondonAges 45–65 - NCT06937749RecruitingPhase 2
Study of IBI362 for liver scarring from MASH
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06868992Recruiting
Study of MASH and cell changes in weight-loss surgery
This study looks at a possible link between MASH (liver inflammation with fat buildup) and tiny cell structures that help liver cells work. Researchers want to understand this better in people having weight-loss surgery, where a small liver sample will be taken.
Lyon, FranceAges 18–99 - NCT06836609RecruitingPhase 1/Phase 2
Study of a new drug for fatty liver disease (MASLD/MASH)
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
Chandler, ArizonaAges 18–65 - NCT06661655Recruiting
Testing a new ultrasound for liver fat in MASLD patients
This study tests a new ultrasound device that uses sound waves to measure fat in the liver without needles or surgery. It is for people with a type of fatty liver disease called MASLD or MASH, who are already getting an MRI to check their liver.
AngersAges 18–80 - NCT06575400RecruitingPhase 1
Testing tolerance of BI 3804379 in healthy people and MASH patients
This study tests how well different doses of a new drug (BI 3804379) are tolerated. It is for healthy people and for patients with MASH (a type of fatty liver disease) who have advanced liver scarring.
EdegemAges 18–65 - NCT06519448Enrolling by invitation
Testing a pill for non-alcoholic fatty liver disease
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
PragueAges 18–75 - NCT06528314RecruitingPhase 3
Efruxifermin for NASH-related cirrhosis
This study tests a new medication called efruxifermin for people with cirrhosis (liver scarring) caused by NASH, a type of fatty liver disease. The goal is to see if the drug can help improve liver health and prevent further damage.
Birmingham, AlabamaAges 18–80 - NCT06419374RecruitingPhase 3
Testing a new drug for liver scarring from MASH
This trial tests a new drug called pegozafermin to see if it can help people with cirrhosis (scarring) of the liver caused by MASH (a fatty liver disease). If you have cirrhosis and either diabetes or multiple risk factors, this study might be an option for you.
Birmingham, AlabamaAges 18–75 - NCT06215716RecruitingPhase 3
Efruxifermin for NASH/MASH with liver scarring
This study tests a new medicine, efruxifermin, for people with NASH/MASH (fatty liver disease) and moderate liver scarring. It aims to see if the drug can help improve the liver's condition.
Birmingham, AlabamaAges 18–80
Hear when a new Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for steatohepatitis?
- Yes. Clin2 currently lists 93 recruiting steatohepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a steatohepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a steatohepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.